Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Viking Therapeutics, Inc.VKTX · Entity 4067 | Director | January 02, 2026 | January 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Viking Therapeutics, Inc.
Report date January 02, 2026 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.00001 per shareSEC Table I · non-derivative | Direct | 12,650 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 3,150 · Balance 12,650 F1: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. All shares subject to the RSU shall vest on the one year anniversary of the grant date of the award. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.42 · Expires 2036-01-02 | Direct | 20,400 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 20,400 · Balance 20,400 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. All shares subject to the RSU shall vest on the one year anniversary of the grant date of the award.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 5, 2026 20:26 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 20,400 | $0.00 Strike: $35.42 | $0.00 |
DisclosureSEC source: 0001193125-26-003112 · ownership.xml · derivative · entry 2 SINGLETON J MATTHEW · CIK 0001243514 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,400 Underlying: Common Stock · 20,400 shares Expires 2036-01-02 Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 20:26 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 3,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-003112 · ownership.xml · nonDerivative · entry 1 SINGLETON J MATTHEW · CIK 0001243514 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,650 F1 · shares: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. All shares subject to the RSU shall vest on the one year anniversary of the grant date of the award. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 20:13 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 18,800 | $0.00 Strike: $41.12 | $0.00 |
DisclosureSEC source: 0000950170-25-002483 · ownership.xml · derivative · entry 1 SINGLETON J MATTHEW · CIK 0001243514 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,800 Underlying: Common Stock · 18,800 shares Expires 2035-01-02 Read SEC document |
| October 25, 2024 Filed Oct 25, 2024 19:27 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $4.48 | $0.00 |
DisclosureSEC source: 0000950170-24-117513 · ownership.xml · derivative · entry 3 SINGLETON J MATTHEW · CIK 0001243514 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person. Read SEC document |
| October 25, 2024 Filed Oct 25, 2024 19:27 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 16,000 | $79.50 | $1,272,000.00 |
DisclosureSEC source: 0000950170-24-117513 · ownership.xml · nonDerivative · entry 2 SINGLETON J MATTHEW · CIK 0001243514 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,500 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person. Read SEC document |
| October 25, 2024 Filed Oct 25, 2024 19:27 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 16,000 | $4.48 | $71,680.00 |
DisclosureSEC source: 0000950170-24-117513 · ownership.xml · nonDerivative · entry 1 SINGLETON J MATTHEW · CIK 0001243514 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person. Read SEC document |
| September 20, 2024 Filed Sep 20, 2024 21:21 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,300 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0000950170-24-108577 · ownership.xml · derivative · entry 3 SINGLETON J MATTHEW · CIK 0001243514 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,300 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person. Read SEC document |
| September 20, 2024 Filed Sep 20, 2024 21:21 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 10,300 | $69.50 | $715,850.00 |
DisclosureSEC source: 0000950170-24-108577 · ownership.xml · nonDerivative · entry 2 SINGLETON J MATTHEW · CIK 0001243514 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,500 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person. Read SEC document |
| September 20, 2024 Filed Sep 20, 2024 21:21 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 10,300 | $1.19 | $12,257.00 |
DisclosureSEC source: 0000950170-24-108577 · ownership.xml · nonDerivative · entry 1 SINGLETON J MATTHEW · CIK 0001243514 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person. Read SEC document |
| August 21, 2024 Filed Aug 22, 2024 19:23 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,700 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0000950170-24-099980 · ownership.xml · derivative · entry 3 SINGLETON J MATTHEW · CIK 0001243514 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,300 Underlying: Common Stock · 5,700 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person. Read SEC document |
| August 21, 2024 Filed Aug 22, 2024 19:23 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 5,700 | $69.72 | $397,430.22 |
DisclosureSEC source: 0000950170-24-099980 · ownership.xml · nonDerivative · entry 2 SINGLETON J MATTHEW · CIK 0001243514 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,500 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.50 to $69.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 21, 2024 Filed Aug 22, 2024 19:23 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 5,700 | $1.19 | $6,783.00 |
DisclosureSEC source: 0000950170-24-099980 · ownership.xml · nonDerivative · entry 1 SINGLETON J MATTHEW · CIK 0001243514 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person. Read SEC document |
| August 19, 2024 Filed Aug 19, 2024 20:11 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $3.33 | $0.00 |
DisclosureSEC source: 0000950170-24-098799 · ownership.xml · derivative · entry 8 SINGLETON J MATTHEW · CIK 0001243514 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2026-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person. Read SEC document |
| August 19, 2024 Filed Aug 19, 2024 20:11 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 1,501 | $64.88 | $97,384.58 |
DisclosureSEC source: 0000950170-24-098799 · ownership.xml · nonDerivative · entry 7 SINGLETON J MATTHEW · CIK 0001243514 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,500 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.79 to $64.9056, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 19, 2024 Filed Aug 19, 2024 20:11 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 2,388 | $64.10 | $153,079.64 |
DisclosureSEC source: 0000950170-24-098799 · ownership.xml · nonDerivative · entry 6 SINGLETON J MATTHEW · CIK 0001243514 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,001 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.64 to $64.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 19, 2024 Filed Aug 19, 2024 20:11 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 2,055 | $63.15 | $129,775.10 |
DisclosureSEC source: 0000950170-24-098799 · ownership.xml · nonDerivative · entry 5 SINGLETON J MATTHEW · CIK 0001243514 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,389 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.635 to $63.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 19, 2024 Filed Aug 19, 2024 20:11 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 4,509 | $61.86 | $278,931.25 |
DisclosureSEC source: 0000950170-24-098799 · ownership.xml · nonDerivative · entry 4 SINGLETON J MATTHEW · CIK 0001243514 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,444 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.5874 to $62.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 19, 2024 Filed Aug 19, 2024 20:11 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 3,047 | $61.13 | $186,248.18 |
DisclosureSEC source: 0000950170-24-098799 · ownership.xml · nonDerivative · entry 3 SINGLETON J MATTHEW · CIK 0001243514 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,953 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.5411 to $61.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 19, 2024 Filed Aug 19, 2024 20:11 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 2,500 | $60.01 | $150,034.50 |
DisclosureSEC source: 0000950170-24-098799 · ownership.xml · nonDerivative · entry 2 SINGLETON J MATTHEW · CIK 0001243514 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.50 to $60.3605, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 19, 2024 Filed Aug 19, 2024 20:11 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 16,000 | $3.33 | $53,280.00 |
DisclosureSEC source: 0000950170-24-098799 · ownership.xml · nonDerivative · entry 1 SINGLETON J MATTHEW · CIK 0001243514 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person. Read SEC document |
| August 14, 2024 Filed Aug 14, 2024 20:03 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,786 | $0.00 Strike: $8.00 | $0.00 |
DisclosureSEC source: 0000950170-24-097325 · ownership.xml · derivative · entry 4 SINGLETON J MATTHEW · CIK 0001243514 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,786 shares Expires 2025-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person. Read SEC document |
| August 14, 2024 Filed Aug 14, 2024 20:03 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 160 | $58.37 | $9,339.01 |
DisclosureSEC source: 0000950170-24-097325 · ownership.xml · nonDerivative · entry 3 SINGLETON J MATTHEW · CIK 0001243514 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,500 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.25 to $58.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 14, 2024 Filed Aug 14, 2024 20:03 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 20,626 | $57.52 | $1,186,397.21 |
DisclosureSEC source: 0000950170-24-097325 · ownership.xml · nonDerivative · entry 2 SINGLETON J MATTHEW · CIK 0001243514 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,660 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.20 to $58.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 14, 2024 Filed Aug 14, 2024 20:03 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 20,786 | $8.00 | $166,288.00 |
DisclosureSEC source: 0000950170-24-097325 · ownership.xml · nonDerivative · entry 1 SINGLETON J MATTHEW · CIK 0001243514 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:28 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 32,000 | $0.00 Strike: $18.28 | $0.00 |
DisclosureSEC source: 0001209191-24-000925 · doc4.xml · derivative · entry 1 SINGLETON J MATTHEW · CIK 0001243514 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2034-01-02 Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 18:13 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $8.52 | $0.00 |
DisclosureSEC source: 0001209191-23-001314 · doc4.xml · derivative · entry 1 SINGLETON J MATTHEW · CIK 0001243514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2033-01-03 Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 19:11 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $4.88 | $0.00 |
DisclosureSEC source: 0001209191-22-001985 · doc4.xml · derivative · entry 1 SINGLETON J MATTHEW · CIK 0001243514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2032-01-03 Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 16:39 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $5.80 | $0.00 |
DisclosureSEC source: 0001209191-21-002124 · doc4.xml · derivative · entry 1 SINGLETON J MATTHEW · CIK 0001243514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2031-01-04 Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 19:59 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $7.95 | $0.00 |
DisclosureSEC source: 0001209191-20-001422 · doc4.xml · derivative · entry 1 SINGLETON J MATTHEW · CIK 0001243514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2030-01-02 Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 20:27 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $8.32 | $0.00 |
DisclosureSEC source: 0001209191-19-001564 · doc4.xml · derivative · entry 1 SINGLETON J MATTHEW · CIK 0001243514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2029-01-02 Read SEC document |
| May 31, 2018 Filed May 31, 2018 19:04 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | PurchaseCommon Stock, par value $0.00001 per share | 9,500 | $9.82 | $93,260.55 |
DisclosureSEC source: 0001209191-18-034496 · doc4.xml · nonDerivative · entry 1 SINGLETON J MATTHEW · CIK 0001243514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500 Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 16:17 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $4.48 | $0.00 |
DisclosureSEC source: 0001209191-18-000853 · doc4.xml · derivative · entry 1 SINGLETON J MATTHEW · CIK 0001243514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2028-01-02 Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 19:17 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001209191-17-002384 · doc4.xml · derivative · entry 1 SINGLETON J MATTHEW · CIK 0001243514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2027-01-03 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.